AU2012319265B2 - Adjuvant compound - Google Patents

Adjuvant compound Download PDF

Info

Publication number
AU2012319265B2
AU2012319265B2 AU2012319265A AU2012319265A AU2012319265B2 AU 2012319265 B2 AU2012319265 B2 AU 2012319265B2 AU 2012319265 A AU2012319265 A AU 2012319265A AU 2012319265 A AU2012319265 A AU 2012319265A AU 2012319265 B2 AU2012319265 B2 AU 2012319265B2
Authority
AU
Australia
Prior art keywords
antigen
peptide
compound according
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012319265A
Other languages
English (en)
Other versions
AU2012319265A1 (en
Inventor
Dmitri Viktorovitsj FILIPPOV
Selina KHAN
Cornelis Johannes Maria Melief
Ferdinand Antonius Ossendorp
Gijsbert Arie Van Der Marel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ISA PHARMACEUTICALS BV
Original Assignee
ISA PHARMACEUTICALS BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ISA PHARMACEUTICALS BV filed Critical ISA PHARMACEUTICALS BV
Publication of AU2012319265A1 publication Critical patent/AU2012319265A1/en
Application granted granted Critical
Publication of AU2012319265B2 publication Critical patent/AU2012319265B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AU2012319265A 2011-10-05 2012-10-04 Adjuvant compound Active AU2012319265B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161543510P 2011-10-05 2011-10-05
US61/543,510 2011-10-05
NL2007536 2011-10-05
NL2007536A NL2007536C2 (en) 2011-10-05 2011-10-05 Adjuvant compound.
US201261615566P 2012-03-26 2012-03-26
US61/615,566 2012-03-26
PCT/NL2012/050694 WO2013051936A1 (en) 2011-10-05 2012-10-04 Adjuvant compound

Publications (2)

Publication Number Publication Date
AU2012319265A1 AU2012319265A1 (en) 2014-05-22
AU2012319265B2 true AU2012319265B2 (en) 2016-10-13

Family

ID=48043964

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012319265A Active AU2012319265B2 (en) 2011-10-05 2012-10-04 Adjuvant compound

Country Status (16)

Country Link
US (2) US9314521B2 (enExample)
EP (1) EP2763697B9 (enExample)
JP (1) JP6099210B2 (enExample)
KR (1) KR102053699B1 (enExample)
CN (1) CN104244976B (enExample)
AU (1) AU2012319265B2 (enExample)
BR (1) BR112014008214B1 (enExample)
CA (1) CA2886631C (enExample)
EA (1) EA030741B1 (enExample)
ES (1) ES2952644T3 (enExample)
IL (1) IL231951B (enExample)
IN (1) IN2014DN03325A (enExample)
MX (1) MX356028B (enExample)
NL (1) NL2007536C2 (enExample)
SG (1) SG11201401291XA (enExample)
WO (1) WO2013051936A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2623979T3 (es) 2013-03-21 2017-07-12 Sanofi-Aventis Deutschland Gmbh Síntesis de productos peptídicos que contienen hidantoína
ES2624961T3 (es) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Síntesis de productos de péptido que contienen imida cíclica
AU2014300503B2 (en) 2013-06-28 2018-11-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CA2950863C (en) 2014-06-02 2023-01-17 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
RU2017126206A (ru) 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
HK1255541A1 (zh) 2015-12-11 2019-08-23 Immatics Biotechnologies Gmbh 用於多种癌症免疫治疗的新型肽和肽组合物
AU2017223267B2 (en) 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2023505304A (ja) 2019-12-07 2023-02-08 アイエスエー ファーマシューティカルズ ビー.ヴイ. B型肝炎ウイルスに関連する疾患の治療
WO2021156404A2 (en) 2020-02-07 2021-08-12 Isa Pharmaceuticals Treatment of hpv-related diseases
WO2021214297A1 (en) 2020-04-23 2021-10-28 Isa Pharmaceuticals B.V. Immunization against sars-cov-related diseases
JP2024525690A (ja) 2021-07-12 2024-07-12 アイエスエー ファーマシューティカルズ ビー.ヴイ. 複雑な混合物中の改善された物質定量
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
EP4601685A1 (en) 2022-10-13 2025-08-20 Isabella Pharma B.V. Modified long peptides suitable for use in immunisation
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025008085A1 (en) 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431327A1 (de) * 1989-11-10 1991-06-12 Hoechst Aktiengesellschaft Synthetische Vakzine zur spezifischen Induktion zytotoxischer T-Lymphozyten

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485094D1 (de) * 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2380873A1 (en) 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NL1012739C2 (nl) 1999-07-29 2001-01-30 Maasland Nv Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer.
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
MXNL04000056A (es) 2004-06-30 2006-01-11 Mario Alberto Aguilera Rico Sistema de construccion terra acero.
AU2007284656A1 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
CN106220721B (zh) 2007-03-26 2020-04-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
EP2468763B1 (en) 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
AU2008257791B2 (en) 2007-05-31 2013-03-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
AU2011232421B2 (en) * 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431327A1 (de) * 1989-11-10 1991-06-12 Hoechst Aktiengesellschaft Synthetische Vakzine zur spezifischen Induktion zytotoxischer T-Lymphozyten

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIDA T. ET AL: "Synthesis and Biological Activities of TAN-1511 Analogues.", THE JOURNAL OF ANTIBIOTICS, vol. 48, no. 7, 1 January 1995, pages 589-603 *
MOYLE P. M. and TOTH I. "Self-Adjuvanting Lipopeptide Vaccines", CURRENT MEDICINAL CHEMISTRY, vol. 15, no. 5, 1 January 2008 , pages 506-516, *

Also Published As

Publication number Publication date
EA030741B1 (ru) 2018-09-28
CA2886631A1 (en) 2013-04-11
KR102053699B1 (ko) 2019-12-09
SG11201401291XA (en) 2014-05-29
ES2952644T3 (es) 2023-11-02
CN104244976B (zh) 2017-05-31
IL231951B (en) 2019-08-29
EA201490709A1 (ru) 2014-09-30
EP2763697C0 (en) 2023-06-07
CN104244976A (zh) 2014-12-24
AU2012319265A1 (en) 2014-05-22
WO2013051936A9 (en) 2013-09-12
CA2886631C (en) 2019-06-11
NZ623869A (en) 2015-11-27
BR112014008214B1 (pt) 2022-07-05
US20160250325A1 (en) 2016-09-01
EP2763697B1 (en) 2023-06-07
KR20140093673A (ko) 2014-07-28
US9314521B2 (en) 2016-04-19
MX356028B (es) 2018-05-09
IN2014DN03325A (enExample) 2015-06-26
JP6099210B2 (ja) 2017-03-22
US20150104473A1 (en) 2015-04-16
MX2014004114A (es) 2014-10-17
NL2007536C2 (en) 2013-04-08
US9770506B2 (en) 2017-09-26
EP2763697B8 (en) 2023-07-12
JP2014530808A (ja) 2014-11-20
IL231951A0 (en) 2014-05-28
EP2763697B9 (en) 2023-10-04
BR112014008214A2 (pt) 2017-06-13
EP2763697A1 (en) 2014-08-13
WO2013051936A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
AU2012319265B2 (en) Adjuvant compound
JP7190528B2 (ja) 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びtlrペプチドアゴニストを含む新規複合体
JP2010059172A (ja) 癌抑制遺伝子wt1の産物に基づく癌抗原
US12016918B2 (en) Peptide-containing adjuvant compounds having peg spacers
NZ623869B2 (en) Improved pam3cys-like lipopeptide adjuvant compound
WO2023220634A2 (en) Uses of amphiphiles in immune cell therapy and compositions therefor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)